Compare ATEC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | XERS |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2006 | 2021 |
| Metric | ATEC | XERS |
|---|---|---|
| Price | $8.32 | $8.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $22.00 | $10.83 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.04 | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $101,739,000.00 | $49,590,000.00 |
| Revenue This Year | $18.97 | $34.37 |
| Revenue Next Year | $16.70 | $22.86 |
| P/E Ratio | ★ N/A | $841.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $6.82 | $4.87 |
| 52 Week High | $23.29 | $10.08 |
| Indicator | ATEC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 56.23 |
| Support Level | $8.10 | $8.00 |
| Resistance Level | $8.42 | $8.42 |
| Average True Range (ATR) | 0.38 | 0.37 |
| MACD | -0.14 | -0.08 |
| Stochastic Oscillator | 12.95 | 30.39 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.